Obinutuzumab trial shows promising results in lupus nephritis patients

California: Researchers discovered that obinutuzumab, an antibody that targets proteins expressed on certain immune cells, was better than placebo at preserving kidney function and preventing flares in patients with lupus nephritis – the autoimmune disease of the kidneys linked to lupus. Status of.

The study was published in Arthritis & Rheumatology, an official journal of the American College of Rheumatology, and a peer-reviewed publication for scientists and physicians interested in the natural history, pathophysiology, treatment, and outcome of rheumatic diseases.

The journal publishes the highest quality basic and clinical research related to rheumatic diseases, covering a wide range of areas of investigative activity.

Researchers found that adding obinutuzumab to the treatment of lupus nephritis reduced the chance of developing the overall outcome of mortality, declining kidney function, or treatment failure by 60 percent compared with standard-care treatment alone.

During the trial, the addition of obinutuzumab reduced the incidence of lupus nephritis recurrence by 57 percent and dramatically reduced the rate of decline in kidney function.

Overall, 16 percent of placebo-treated patients compared with 38 percent of obinutuzumab-treated patients achieved complete remission of lupus nephritis by week 76, with the need for fewer glucocorticoids.

Corresponding author Brad Rovin, MD, of The Ohio State University Wexner, said, “These data are really important because the ultimate goal of lupus nephritis therapy is to preserve kidney survival so that patients do not face the need for dialysis or transplantation because their The kidneys were damaged.” Medical Center.

“The addition of obinutuzumab to standard lupus nephritis therapy may increase the chances of achieving this goal.”